RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin

English version České info

Although statin drugs are generally efficacious for lowering plasma LDL-cholesterol levels, there is considerable variability in response. To identify candidate genes that may contribute to this variation, we used an unbiased genome-wide filter approach that was applied to 10,149 genes expressed in immortalized lymphoblastoid cell lines (LCLs) derived from 480 participants of the Cholesterol and Pharmacogenomics (CAP) clinical trial of simvastatin. The criteria for identification of candidates included genes whose statin-induced changes in expression were correlated with change in expression of HMGCR, a key regulator of cellular cholesterol metabolism and the target of statin inhibition. This analysis yielded 45 genes, from which RHOA was selected for follow-up because it has been found to participate in mediating the pleiotropic but not the lipid-lowering effects of statin treatment. RHOA knock-down in hepatoma cell lines reduced HMGCR, LDLR, and SREBF2 mRNA expression and increased intracellular cholesterol ester content as well as apolipoprotein B (APOB) concentrations in the conditioned media. Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Moreover, the minor allele of rs11716445, a SNP located in a novel cryptic RHOA exon, dramatically increased inclusion of the exon in RHOA transcripts during splicing and was associated with a smaller LDL-cholesterol reduction in response to statin treatment in 1,886 participants from the CAP and Pravastatin Inflamation and CRP Evaluation (PRINCE; pravastatin 40 mg/d) statin clinical trials. Thus, an unbiased filter approach based on transcriptome-wide profiling identified RHOA as a gene contributing to variation in LDL-cholesterol response to statin, illustrating the power of this approach for identifying candidate genes involved in drug response phenotypes.

Vyšlo v časopise: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS Genet 8(11): e32767. doi:10.1371/journal.pgen.1003058
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003058

Souhrn

Zdroje

1. AltshulerD, DalyMJ, LanderES (2008) Genetic mapping in human disease. Science 322: 881–888.

2. AmosCI (2007) Successful design and conduct of genome-wide association studies. Hum Mol Genet 16 Spec No. 2: R220–225.

3. ThompsonJF, HydeCL, WoodLS, PacigaSA, HindsDA, et al. (2009) Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort. Circulation Cardiovascular Genetics 2: 173–181.

4. TanakaY, NishidaN, SugiyamaM, KurosakiM, MatsuuraK, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.

5. ChasmanDI, GiulianiniF, MacfadyenJ, BarrattBJ, NybergF, et al. (2012) Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circ Cardiovasc Genet 5: 257–264.

6. GoldsteinJL, BrownMS (1990) Regulation of the mevalonate pathway. Nature 343: 425–430.

7. GoldsteinJL, BrownMS, AndersonRG, RussellDW, SchneiderWJ (1985) Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1: 1–39.

8. BrownMS, GoldsteinJL (1985) The LDL receptor and HMG-CoA reductase–two membrane molecules that regulate cholesterol homeostasis. Curr Top Cell Regul 26: 3–15.

9. SimonJA, LinF, HulleySB, BlanchePJ, WatersD, et al. (2006) Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 97: 843–850.

10. GuillaumotP, LuquainC, MalekM, HuberAL, BrugiereS, et al. (2010) Pdro, a protein associated with late endosomes and lysosomes and implicated in cellular cholesterol homeostasis. PLoS ONE 5: e10977 doi:10.1371/journal.pone.0010977

11. OkuhiraK, FitzgeraldML, TamehiroN, OhokaN, SuzukiK, et al. (2010) Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J Biol Chem 285: 16369–16377.

12. BartzF, KernL, ErzD, ZhuM, GilbertD, et al. (2009) Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab 10: 63–75.

13. AltshulerDM, GibbsRA, PeltonenL, DermitzakisE, SchaffnerSF, et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52–58.

14. BarrettJC, FryB, MallerJ, DalyMJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.

15. ArgmannCA, EdwardsJY, SawyezCG, O'NeilCH, HegeleRA, et al. (2005) Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 280: 22212–22221.

16. CoreyDA, KelleyTJ (2007) Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts. Biochim Biophys Acta 1772: 748–754.

17. HoshinoD, TomariT, NaganoM, KoshikawaN, SeikiM (2009) A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling, and matrigel invasion. J Biol Chem 284: 27315–27326.

18. OliyarnykO, RennerW, PaulweberB, WascherTC (2005) Interindividual differences of response to statin treatment cannot be explained by variations of the human gene for RhoA. Biochem Genet 43: 143–148.

19. IharaK, MuraguchiS, KatoM, ShimizuT, ShirakawaM, et al. (1998) Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J Biol Chem 273: 9656–9666.

20. RittingerK, WalkerPA, EcclestonJF, SmerdonSJ, GamblinSJ (1997) Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue. Nature 389: 758–762.

21. SmithPJ, ZhangC, WangJ, ChewSL, ZhangMQ, et al. (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15: 2490–2508.

22. ChandradasS, DeikusG, TardosJG, BogdanovVY (2010) Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. J Leukoc Biol 87: 147–152.

23. MedinaMW, GaoF, RuanW, RotterJI, KraussRM (2008) Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118: 355–362.

24. MasonRP, WalterMF, DayCA, JacobRF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96: 11F–23F.

25. BrownMS, FaustJR, GoldsteinJL, KanekoI, EndoA (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253: 1121–1128.

26. MangraviteLM, MedinaMW, CuiJ, PressmanS, SmithJD, et al. Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin. Arterioscler Thromb Vasc Biol 30 (7): 1485–92.

27. TusherVG, TibshiraniR, ChuG (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116–5121.

28. LeekJT, StoreyJD (2008) A general framework for multiple testing dependence. Proc Natl Acad Sci U S A 105: 18718–18723.

29. InnocentiF, CooperGM, StanawayIB, GamazonER, SmithJD, et al. (2011) Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet 7: e1002078 doi:10.1371/journal.pgen.1002078

30. MedinaMW, GaoF, NaidooD, RudelLL, TemelRE, et al. (2011) Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake. PLoS ONE 6: e19420 doi/10.1371/journal.pone.0019420.

31. BarberM, MangraviteL, HydeCL, ChasmanDI, SmithJD, et al. (2010) Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 5: e9763 doi:10.1371/journal.pone.0009763

32. ChasmanDI, PosadaD, SubrahmanyanL, CookNR, StantonVPJr, et al. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. Jama 291: 2821–2827.

33. JohnsonAD, HandsakerRE, PulitSL, NizzariMM, O'DonnellCJ, et al. (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24: 2938–2939.

34. CartegniL, WangJ, ZhuZ, ZhangMQ, KrainerAR (2003) ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 31: 3568–3571.